Stock Traders Buy Large Volume of Davita Call Options (NYSE:DVA)

Davita Inc (NYSE:DVA) saw unusually large options trading on Thursday. Investors acquired 18,870 call options on the stock. This is an increase of 1,078% compared to the typical daily volume of 1,602 call options.

Davita stock traded up $0.62 during midday trading on Friday, reaching $56.44. The company had a trading volume of 1,430,114 shares, compared to its average volume of 2,124,232. The company has a market capitalization of $8.85 billion, a P/E ratio of 15.81, a P/E/G ratio of 0.55 and a beta of 1.60. Davita has a 12-month low of $43.40 and a 12-month high of $79.11. The firm’s fifty day simple moving average is $57.72 and its 200-day simple moving average is $54.94. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.12 and a quick ratio of 1.10.

Davita (NYSE:DVA) last issued its quarterly earnings results on Thursday, August 1st. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.12. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. Davita’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period last year, the company posted $1.05 EPS. On average, analysts expect that Davita will post 4.78 EPS for the current fiscal year.

Several equities research analysts have weighed in on DVA shares. Robert W. Baird downgraded Davita from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $70.00 to $65.00 in a research report on Friday, July 26th. UBS Group cut their price target on Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. ValuEngine raised Davita from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. William Blair lowered shares of Davita from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 11th. Finally, TheStreet raised shares of Davita from a “c+” rating to a “b-” rating in a research note on Wednesday, July 24th. Eight analysts have rated the stock with a hold rating and two have given a buy rating to the company. Davita currently has an average rating of “Hold” and an average target price of $65.35.

A number of hedge funds have recently added to or reduced their stakes in DVA. Rehmann Capital Advisory Group increased its holdings in Davita by 467.3% in the 1st quarter. Rehmann Capital Advisory Group now owns 556 shares of the company’s stock valued at $30,000 after purchasing an additional 458 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Davita by 63.5% in the 1st quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock valued at $43,000 after purchasing an additional 310 shares during the last quarter. North Star Investment Management Corp. acquired a new stake in Davita in the 3rd quarter valued at approximately $46,000. CSat Investment Advisory L.P. increased its holdings in Davita by 54.0% in the 1st quarter. CSat Investment Advisory L.P. now owns 895 shares of the company’s stock valued at $49,000 after purchasing an additional 314 shares during the last quarter. Finally, Employers Holdings Inc. acquired a new stake in Davita in the 2nd quarter valued at approximately $56,000. Institutional investors own 90.71% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: Golden Cross

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.